Combination immunotherapy including OncoVEX mGMCSF creates a favorable tumor immune micro-environmen...
Combination immunotherapy including OncoVEX mGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma
About this item
Full title
Author / Creator
Gartrell, Robyn D , Blake, Zoë , Rizk, Emanuelle M , Perez-Lorenzo, Rolando , Weisberg, Stuart P , Simoes, Ines , Esancy, Camden , Fu, Yichun , Davari, Danielle R , Barker, Luke , Finkel, Grace , Mondal, Manas , Minns, Hanna E , Wang, Samuel W , Fullerton, Benjamin T , Lozano, Francisco , Chiuzan, Codruta , Horst, Basil and Saenger, Yvonne M
Publisher
Germany
Journal title
Language
English
Formats
Publication information
Publisher
Germany
Subjects
More information
Scope and Contents
Contents
Talimogene Laherparepvec (OncoVEX
), an oncolytic virus, immune checkpoint inhibitor anti-programmed cell death protein 1 (anti-PD1), and BRAF inhibition (BRAFi), are all clinically approved for treatment of melanoma patients and are effective through diverse mechanisms of action. Individually, these therapies also have an effect on the tumor im...
Alternative Titles
Full title
Combination immunotherapy including OncoVEX mGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma
Authors, Artists and Contributors
Author / Creator
Blake, Zoë
Rizk, Emanuelle M
Perez-Lorenzo, Rolando
Weisberg, Stuart P
Simoes, Ines
Esancy, Camden
Fu, Yichun
Davari, Danielle R
Barker, Luke
Finkel, Grace
Mondal, Manas
Minns, Hanna E
Wang, Samuel W
Fullerton, Benjamin T
Lozano, Francisco
Chiuzan, Codruta
Horst, Basil
Saenger, Yvonne M
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_34999916
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_34999916
Other Identifiers
E-ISSN
1432-0851
DOI
10.1007/s00262-021-03088-y
